A Clinical Randomized Control Study Of "Lanzhou Fang" Combined With Chemoth-erapy In The Treatment Of Advanced Non S-mall Cell Lung Cancer

Objective: To observe Lanzhou prescription combined with chemotherapy for advancednon-small cell lung cancer clinical efficacy, provide adequate scientific basis for its widelyused in clinical.Methods: According to the order of admission of60patients with advanced non-smallcell lung cancer patients were randomly divided into control group (conventionalchemotherapy group) and treatment group (control group on the basis of additional servicesthe Lanzhou prescription), The control group with NP chemotherapy (vinorelbine (NVB)25mg/m2, on days1,8, administered by deep vein; cisplatin (DDP)30mg/m2, apply1to3days,21days for chemotherapy courses of two courses) and symptomatic and supportivetreatment. Treatment group on the basis of the control group on the use of Lanzhouprescription, the use of extracting machine, each dose of dextrose2pack, early, after dinner,each serving a pack. The main clinical symptoms in patients with changes observed after theend of treatment, Karnofsky score, treatment in mortality, a comparative analysis of theefficacy of the two groups of patients.Results:1patient after treatment toxicity treatment group reduced side effects (P<0.05),the Lanzhou prescription can significantly reduce the side effects of chemotherapy.2After the end of treatment studies in patients CD++3、CD4and CD+4/CD+8, NK cells wassignificantly increased, there are differences (P<0.05), the control group before and aftertreatment of T cell subsets was no difference (P>0.05).3After the end of treatment in patients treated with Karnofsky score, body mass than thecontrol group improved significantly (P<0.05), indicating that the treatment group patientsquality of life has been significantly improved.4After the treatment, the quality of life of patients studied total score, functional statuscompared with control group, the difference was statistically significant (P<0.05); comparephysical condition, emotional status, symptoms/side effects of the treatment group and thecontrol group after treatment, differences were statistically significant (P<0.01). After thetreatment group therapy social/family status, compared with the doctor’s relationship withthe control group, the difference was not significant (P>0.05). 5After the end of treatment in patients treated with adverse reaction reduced (P<0.05);treatment group and the control group, cough, chest pain was no significant difference (P>0.05).6After the treatment of tumors in patients with recent treatment group response rate (CR+PR/n) treatment group was43.33%, and40.00%in the control group, there were nodifferences between the two groups (P>0.05).7After the treatment, the treatment group compared with the control group in thetreatment mortality rate is low, indicating that the increase in the survival of patients in thetreatment group.Conclusion: Lanzhou prescription combined with chemotherapy can reduce the sideeffects of chemotherapy for advanced non-small cell lung cancer patients, improve clinicalsymptoms, improve their quality of life and reduce mortality in the treatment and prolongsurvival. Lanzhou prescription combined with chemotherapy to treat advanced non-small celllung cancer synergies.